The AFI 2022 Symposium, aimed at its 61st edition, was held from 8 to 10 June. As per tradition, it took place at the Rimini conference center. The 12 scientific sessions touched on the most diverse topics: from clinical research, to technological innovation, from APIs to supplements, from regulatory affairs to quality, from drugs to medical devices.
We went to follow the session of Thursday 9 reserved for pharmacovigilance for you. Here’s what we talked about.

Pharmacovigilance: from the Risk Minimization Plan to information material

The AFI Symposium 2022 title was “The Pharmaceutical World: the paradigms of a new era”. Therefore, the sessions could only turn on the return to normality. For pharmacovigilance, one of the most challenging activities now is the implementation of the “additional Risk Minimization Measures – aRMM”. The session, therefore, dealt with the risk minimization activity in all its aspects, from the point of view of all the stakeholders involved: the pharmaceutical company, the authority, the healthcare worker and the patient.

The session started with an introduction by dr. Oliva di Mylan, who dedicated the session to the memory of Dr. Pimpinella, manager of the AIFA Pharmacovigilance Office, recently deceased. After to speak was Dr. Cagnato of DOC Generici. She explained how the Risk Management Plan activity is carried out by her pharmaceutical company. To follow, dr. Diana of AIFA exposed the approach of the Regulatory Authority.

To evaluate the point of view of the pharmaceutical company with respect to that of the patient, there was an interesting double interview. It was held by Veronica Franchina of A.O. Papardo, to Dr. Pappalardo of AUSL Romagna and to Dr. Patrucco di Sofar and experienced patient Eupati. She asked them questions about the importance of the information material.

To conclude the session there was a round table. Here all the exponents of the various sectors discussed the issues of the individual interventions and answer questions from the public.